NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
YRC Worldwide Inc. (NASDAQGS: YRCW)
Class Period: March 10, 2014 - December 14, 2018
Lead Plaintiff Deadline: March 4, 2019
Join the action: https://www.zlk.com/pslra-1/yrc-worldwide-inc-loss-form?wire=3
Allegations: YRC Worldwide Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) from 2005
to at least 2013, YRC's units systematically overcharged the federal government for freight carrier services; (2) this alleged
misconduct caused the Department of Defense to overpay by millions of dollars for shipments that were lighter, and thus cheaper,
than the weights for which the government was charged; (3) consequently, this alleged misconduct would subject YRC to enhanced
government scrutiny and liabilities, including potentially owing treble damages under the False Claims Act; and (4) as a result,
the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the YRC Worldwide Inc. class action contact jlevi@levikorsinsky.com.
Immunomedics, Inc. (NASDAQ: IMMU)
Class Period: February 8, 2018 - January 18, 2019
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3
Allegations: Immunomedics, Inc. made materially false and/or misleading statements throughout the class period and/or failed to
disclose that: (i) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA
requirements; (ii) the Company’s Quality Control Unit did not possess the authority to investigate and correct critical FDA
violations occurring at the Morris Plains, New Jersey facility; (iii) the Company suffered a February 2018 data integrity breach at
the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden
samples; (iv) the Company’s Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab
govitecan was insufficient to support FDA approval; and (v) as a result, the Company’s public statements were materially false and
misleading at all relevant times.
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.
Markel Corporation (NYSE: MKL)
Class Period: July 26, 2017 - December 6, 2018
Lead Plaintiff Deadline: March 12, 2019
Join the action: https://www.zlk.com/pslra-1/markel-corporation-loss-form?wire=3
Allegations: During the class period, Markel Corporation made materially false and/or misleading statements and/or failed to
disclose that: (1) the Company’s subsidiaries did not appropriately record loss reserves; (2) as a result, the loss reserves would
need to be adjusted and/or restated; (3) these misleading accounting practices would lead to regulatory scrutiny and financial loss
to investors; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and
prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the Markel Corporation class action contact jlevi@levikorsinsky.com.
Maiden Holdings, Ltd. (NASDAQGS: MHLD)
Class Period: March 4, 2014 - November 9, 2018
Lead Plaintiff Deadline: April 12, 2019
Join the action: https://www.zlk.com/pslra-1/maiden-holdings-ltd-loss-form?wire=3
The complaint alleges that during the Class Period, defendants misrepresented the quality and nature of Maiden’s underwriting
and risk management policies and practices and the risks of its reinsurance portfolio. In particular, defendants misleadingly
claimed that they were subjecting AmTrust’s insurance portfolio to robust analysis and cross-checks to ensure that the Company had
appropriately priced the risk of reinsuring AmTrust’s insurance portfolio. In truth, the Company had failed to employ sufficient
underwriting and risk management protocols and had largely abdicated its responsibility to ensure that its AmTrust Reinsurance
segment priced policies commensurate with the risk assumed by the Company.
To learn more about the Maiden Holdings, Ltd. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
